Sawtooth Solutions LLC Purchases 5,295 Shares of AstraZeneca plc (NYSE:AZN)

Sawtooth Solutions LLC increased its stake in shares of AstraZeneca plc (NYSE:AZN) by 32.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,812 shares of the company’s stock after purchasing an additional 5,295 shares during the quarter. Sawtooth Solutions LLC’s holdings in AstraZeneca were worth $882,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC raised its holdings in shares of AstraZeneca by 59.6% during the fourth quarter. FMR LLC now owns 56,373,971 shares of the company’s stock worth $2,141,084,000 after acquiring an additional 21,048,181 shares during the period. Jennison Associates LLC increased its stake in AstraZeneca by 15.2% in the 4th quarter. Jennison Associates LLC now owns 45,796,787 shares of the company’s stock valued at $1,739,362,000 after buying an additional 6,052,483 shares during the last quarter. GQG Partners LLC increased its stake in AstraZeneca by 11.5% in the 4th quarter. GQG Partners LLC now owns 2,998,017 shares of the company’s stock valued at $113,973,000 after buying an additional 309,229 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in AstraZeneca by 3.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,678,067 shares of the company’s stock valued at $101,713,000 after buying an additional 80,891 shares during the last quarter. Finally, Parametric Portfolio Associates LLC increased its stake in AstraZeneca by 6.0% in the 1st quarter. Parametric Portfolio Associates LLC now owns 2,606,557 shares of the company’s stock valued at $105,383,000 after buying an additional 147,559 shares during the last quarter. 18.79% of the stock is currently owned by institutional investors and hedge funds.

AZN stock traded up $0.29 during trading on Friday, reaching $41.28. 2,304,800 shares of the company were exchanged, compared to its average volume of 4,802,218. The business’s 50-day moving average is $39.08. The company has a market capitalization of $103.82 billion, a P/E ratio of 11.93, a price-to-earnings-growth ratio of 1.26 and a beta of 0.47. AstraZeneca plc has a twelve month low of $34.40 and a twelve month high of $43.29. The company has a debt-to-equity ratio of 1.48, a current ratio of 0.75 and a quick ratio of 0.58.

AstraZeneca (NYSE:AZN) last posted its earnings results on Friday, April 26th. The company reported $0.45 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.43 by $0.02. AstraZeneca had a net margin of 10.75% and a return on equity of 37.91%. The firm had revenue of $5.47 billion for the quarter, compared to analyst estimates of $5.40 billion. During the same period in the previous year, the firm posted $0.48 EPS. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. As a group, research analysts forecast that AstraZeneca plc will post 1.78 earnings per share for the current fiscal year.

Several equities research analysts have issued reports on AZN shares. Zacks Investment Research upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research note on Thursday, April 4th. Main First Bank reaffirmed a “buy” rating on shares of AstraZeneca in a report on Tuesday, March 19th. ValuEngine downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a report on Monday, April 1st. Pareto Securities raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Monday, April 29th. Finally, Cowen raised shares of AstraZeneca from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $42.00 to $48.00 in a report on Monday, April 1st. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $45.29.

AstraZeneca Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Article: Yield Curve

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.